Body composition, abdominal fat distribution, and prostate-specific antigen test results

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 1, 2009, Pages 331-336

  Rundle, Andrew ^a   Richards, Catherine ^a   Neugut, Alfred I ^a,b  

^a Mailman School of Public Health   (United States)

^b Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CONTROLLED STUDY; ETHNIC DIFFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING TEST; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; BODY COMPOSITION; ELECTRIC IMPEDANCE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN;

EID: 58349117690     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0247     Document Type: Article

References (64)

1. Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology 2005;65:433-9.
2. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
3. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
4. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005;23:7546-54.
5. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
6. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
7. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-37.
8. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-80.
9. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008;68:373-80.
10. Fowke JH, Motley SS, Cookson MS, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2007;10:137-42.
11. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007;16:70-6.
12. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97.
13. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006;106:320-8.
14. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-5.
15. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998;22:1145-58.
16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
17. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992;2:675-82.
18. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002;11:1041-7.
19. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-7.
20. Blouin K, Richard C, Belanger C, et al. Local androgen inactivation in abdominal visceral adipose tissue. J Clin Endocrinol Metab 2003;88:5944-50.
21. Tchernof A, Labrie F, Belanger A, Despres JP. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol 1996;150 Suppl:S155-64.
22. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006;65:125-31.
23. Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155:443-52.
24. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5:98-102.
25. Simpson ER, Mendelson CR. Effect of aging and obesity on aromatase activity of human adipose cells. Am J Clin Nutr 1987;45:290-5.
26. Longcope C, Baker R, Johnston CC, Jr. Androgen and estrogen metabolism: relationship to obesity. Metabolism 1986;35:235-7.
27. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 2003;149:583-9.
28. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008;70:358-60.
29. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979;48:633-8.
30. Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999;6:315-24.
31. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993;11:188-91.
32. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714-9.
33. Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology 2002;60:464-8.
34. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J 2002;16:1429-31.
35. Vijayakumar S, Quadri SF, Dong L, et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc 1995;87:813-9.
36. Sofikerim M, Oruc O, Eskicorapci S, Guliyev F, Ozen H. Correlation of serum androgens and pituitary hormone levels with serum PSA less than 2.5 ng/ml. ScientificWorldJournal 2007;7:1128-33.
37. Bleau G, Roberts KD, Chapdelaine A. The in vitro and in vivo uptake and metabolism of steroids in human adipose tissue. J Clin Endocrinol Metab 1974;39:236-46.
38. Perel E, Killinger DW. The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem 1979;10:623-7.
39. Brown M. Skeletal muscle and bone: effect of sex steroids and aging. Adv Physiol Educ 2008;32:120-6.
40. Miller KK. Androgen deficiency: effects on body composition. Pituitary 2008 Apr 18 [Epub ahead of print].
41. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150-62.
42. von Eyben FE, Mouritsen E, Holm J, et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord 2003;27:941-9.
43. Bock JL, Klee GG. How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? Arch Pathol Lab Med 2004;128:341-3.
44. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985;41:810-7.
45. Johnstone AM, Murison SD, Duncan JS, Rance KA, Speakman JR. Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am J Clin Nutr 2005;82:941-8.
46. Westerterp KR, Meijer GA, Kester AD, Wouters L, ten Hoor F. Fat-free mass as a function of fat mass and habitual activity level. Int J Sports Med 1992;13:163-6.
47. von Hafe P, Pina F, Perez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 2004;12:1930-5.
48. Tice JA, Kanaya A, Hue T, et al. Risk factors for mortality in middle-aged women. Arch Intern Med 2006;166:2469-77.
49. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Cancer Causes Control 2007;18:399-413.
50. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;10:15-32.
51. Ando R, Nagaya T, Hashimoto Y, et al. Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004-2006. Urology 2008;72:561-5.
52. Jebb SA, Cole TJ, Doman D, Murgatroyd PR, Prentice AM. Evaluation of the novel Tanita body-fat analyser to measure body composition by comparison with a four-compartment model. Br J Nutr 2000;83:115-22.
53. Pietrobelli A, Rubiano F, St-Onge MP, Heymsfield SB. New bioimpedance analysis system: improved phenotyping with whole-body analysis. Eur J Clin Nutr 2004;58:1479-84.
54. Xie X, Kolthoff N, Barenholt O, Nielsen SP. Validation of a leg-to-leg bioimpedance analysis system in assessing body composition in postmenopausal women. Int J Obes Relat Metab Disord 1999;23:1079-84.
55. Nunez C, Gallagher D, Visser M, Pi-Sunyer FX, Wang Z, Heymsfield SB. Bioimpedance analysis: evaluation of leg-to-leg system based on pressure contact footpad electrodes. Med Sci Sports Exerc 1997;29:524-31.
56. Cable A, Nieman DC, Austin M, Hogen E, Utter AC. Validity of leg-to-leg bioelectrical impedance measurement in males. J Sports Med Phys Fitness 2001;41:411-4.
57. Jebb SA, Siervo M, Murgatroyd PR, Evans S, Fruhbeck G, Prentice AM. Validity of the leg-to-leg bioimpedance to estimate changes in body fat during weight loss and regain in overweight women: a comparison with multi-compartment models. Int J Obes (Lond) 2007;31:756-62.
58. Chouinard LE, Schoeller DA, Watras AC, Clark RR, Close RN, Buchholz AC. Bioelectrical impedance vs. four-compartment model to assess body fat change in overweight adults. Obesity (Silver Spring) 2007;15:85-92.
59. Powell LA, Nieman DC, Melby C, et al. Assessment of body composition change in a community-based weight management program. J Am Coll Nutr 2001;20:26-31.
60. Utter AC, Nieman DC, Ward AN, Butterworth DE. Use of the leg-to-leg bioelectrical impedance method in assessing body-composition change in obese women. Am J Clin Nutr 1999;69:603-7.
61. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis - part I: review of principles and methods. Clin Nutr 2004;23:1226-43.
62. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis - part II: utilization in clinical practice. Clin Nutr 2004;23:1430-53.
63. Schoeller DA. Bioelectrical impedance analysis. What does it measure? Ann N Y Acad Sci 2000;904:159-62.
64. Chumlea WC, Guo SS, Kuczmarski RJ, et al. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord 2002;26:1596-609.